Search results for: Eli Lilly
Filter search results
Prevention in the NHS 10 Year Health Plan: Promise, limits, and the path forward
17 September 2025
…population through immunisation, including: Increasing uptake of HPV vaccines to support the aim of eliminating cervical cancer by 2040 Delivering 10,000 cancer vaccines to patients in clinical trials in the…
A global landscape analysis of access to tumour-agnostic therapies
1 December 2025
…Critical: Adoption of advanced diagnostic infrastructure is essential to identifying eligible patients. Testing access is uneven and often depends on the targeted therapies available in the clinical setting, with significant…
Novel devices: optimising drug delivery in multiple myeloma
9 December 2025
…pre-programmed doses subcutaneously over a set period, eliminating the need for manual injections. OBIs provide distinct advantages to the patient over conventional syringe administration. For example, OBIs accommodate high-volume formulations,…
Global rare‑disease policy shifts: what are the implications for equitable access to orphan medicines?
1 March 2026
…2019, and its role in rare disease research has been particularly foundational. As of June 2025, approximately 2,300 NIH grants—for a total of $3.8 billion—in funding were terminated in an effort to eliminate…
Around The World in HTAs: France – Three Core HTA Values
12 March 2026
…pathway, manufacturers may apply to the Early Access Authorisation(Autorisation d’Acces Précoce, AAP) programme, managed by HAS, which allows access to promising therapies up to two years before market authorisation. Eligibility requires…
Seven reflections on the UK EQ-5D-5L value set – and what comes next
30 March 2026
…Value sets are generated from individual-level preference elicitation tasks, in which members of the public are asked to consider their own health from a personal perspective. In contrast, priority setting…
Around the World in HTAs: Japan – An algorithmic approach to containing costs
14 April 2026
…consider the outcome of the report and its implications for their intended expansion of CEA – both in terms of eligible products and the potential shift from premium-based to total…
Valuing patient and carer time in HTA: equity and opportunity cost
15 May 2026
…Adopting a blinkered perspective on value and simply ignoring some inputs to the healthcare production function will not lead to a fair and efficient allocation of resources. Likewise, it will not eliminate inequities in access to treatments based on productivity and is likely…
Unlocking the broader value of biologic therapies through biosimilar-enabled access and repositioning
23 September 2026
…eligible populations or treatment positioning. The research thereby addresses an important gap in the prevailing narrative. When biosimilar competition lowers the cost of a biologic, it can do more than…